Data Trends 2024: Age-Related Macular Degeneration (AMD)

Article Type

Article

Changed

Wed, 08/14/2024 - 13:34

Display Headline

Data Trends 2024: Age-Related Macular Degeneration (AMD)

Click to view more from Federal Health Care Data Trends 2024.

References

Rein DB, Wittenborn JS, Burke-Conte Z, et al. Prevalence of age-related macular degeneration in the US in 2019. JAMA Ophthalmol. 2022;140(12):1202-1208. doi:10.1001/jamaophthalmol.2022.4401
Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA. 2024;331(2):147-157. doi:10.1001/jama.2023.26074
Meer EA, Targ S, Zhang N, Hoggatt KJ, Mehta KM, Brodie F. Age-related macular degeneration injection frequency: effects of distance traveled and travel support. Retina. 2024;44(2):230-236. doi:10.1097/IAE.0000000000003947
Bhisitkul RB, Mendes TS, Rofagha S, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol. 2015;159(5):915-24.e2. doi:10.1016/j.ajo.2015.01.032

Author and Disclosure Information

Reviewed by:

Frank Brodie, MD, MBA
Assistant Professor
Department of Ophthalmology
University of California
San Francisco, CA

Dr. Brodie has disclosed the following relevant financial relationships:
Received research grant from: Genentech
Have a 5% or greater equity interest in: Genentech; Bausch & Lomb; Alimera; Abbvie

Publications

Federal Practitioner

Author and Disclosure Information

Reviewed by:

Frank Brodie, MD, MBA
Assistant Professor
Department of Ophthalmology
University of California
San Francisco, CA

Dr. Brodie has disclosed the following relevant financial relationships:
Received research grant from: Genentech
Have a 5% or greater equity interest in: Genentech; Bausch & Lomb; Alimera; Abbvie

Author and Disclosure Information

Reviewed by:

Frank Brodie, MD, MBA
Assistant Professor
Department of Ophthalmology
University of California
San Francisco, CA

Dr. Brodie has disclosed the following relevant financial relationships:
Received research grant from: Genentech
Have a 5% or greater equity interest in: Genentech; Bausch & Lomb; Alimera; Abbvie

Click to view more from Federal Health Care Data Trends 2024.

References

Rein DB, Wittenborn JS, Burke-Conte Z, et al. Prevalence of age-related macular degeneration in the US in 2019. JAMA Ophthalmol. 2022;140(12):1202-1208. doi:10.1001/jamaophthalmol.2022.4401
Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA. 2024;331(2):147-157. doi:10.1001/jama.2023.26074
Meer EA, Targ S, Zhang N, Hoggatt KJ, Mehta KM, Brodie F. Age-related macular degeneration injection frequency: effects of distance traveled and travel support. Retina. 2024;44(2):230-236. doi:10.1097/IAE.0000000000003947
Bhisitkul RB, Mendes TS, Rofagha S, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol. 2015;159(5):915-24.e2. doi:10.1016/j.ajo.2015.01.032

References

Rein DB, Wittenborn JS, Burke-Conte Z, et al. Prevalence of age-related macular degeneration in the US in 2019. JAMA Ophthalmol. 2022;140(12):1202-1208. doi:10.1001/jamaophthalmol.2022.4401
Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA. 2024;331(2):147-157. doi:10.1001/jama.2023.26074
Meer EA, Targ S, Zhang N, Hoggatt KJ, Mehta KM, Brodie F. Age-related macular degeneration injection frequency: effects of distance traveled and travel support. Retina. 2024;44(2):230-236. doi:10.1097/IAE.0000000000003947
Bhisitkul RB, Mendes TS, Rofagha S, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol. 2015;159(5):915-24.e2. doi:10.1016/j.ajo.2015.01.032